journal article·2015-07-04Open access

The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer

Bina Gidwani, Amber Vyas

Abstract

Ovarian cancer is one of the leading causes for death of women. Every year the percentage of mortality rate is increasing day by day. Various chemotherapeutic agents are used to increase the survival rate of patients with ovarian cancer, but the available conventional dosage forms/marketed preparations are associated with several limitations. The use of nanotechnology in drug delivery contributes to their small size (10-100 nm), which improves the circulation and enables superior accumulation of therapeutic drugs at the tumor sites. In future, the use of nanotechnology will enable passive targeting and further improvements can be made using targeting moieties.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (57)

Show source-provided references
1. 10.3923/pjbs.2012.341.34610.3923/pjbs.2012.341.346 ↗
2. 10.1634/theoncologist.7-suppl_5-2010.1634/theoncologist.7-suppl_5-20 ↗
3. 10.1615/CritRevTherDrugCarrierSyst.v23.i6.1010.1615/CritRevTherDrugCarrierSyst.v23.i6.10 ↗
4. Bayindir ZS · J Pharm Sci · 2010 · 99 · 204910.1002/jps.21944 ↗
5. 10.1002/1097-0142(19811101)48:9<1947::AID-CNCR2820480906>3.0.CO;2-M10.1002/1097-0142(19811101)48:9<1947::AID-CNCR2820480906>3.0.CO;2-M ↗
6. 10.1023/A:102015933142010.1023/A:1020159331420 ↗
7. 10.1126/science.146.3643.52410.1126/science.146.3643.524 ↗
8. Chang TMS. 2007. Monograph on “Artificial Cells: Biotechnology, nanotechnology, blood substitutes, regenerative medicine, bioencapsulation, cell/stem cell therapy.” Singapore and London: World Scientific Publisher/Imperial College Press, p. 435.
9. Chang TMS · 2013 · 3659
10. Chang TMS · J Bioeng · 1976 · 1 · 25
11. 10.1186/1757-2215-2-2110.1186/1757-2215-2-21 ↗
12. 10.1016/j.ygyno.2011.03.03610.1016/j.ygyno.2011.03.036 ↗
13. 10.1634/theoncologist.7-suppl_5-1110.1634/theoncologist.7-suppl_5-11 ↗
14. 10.1155/2012/35878210.1155/2012/358782 ↗
15. 10.1016/S0009-2509(03)00234-310.1016/S0009-2509(03)00234-3 ↗
16. 10.1016/S0959-8049(01)00171-X10.1016/S0959-8049(01)00171-X ↗
17. 10.1016/j.addr.2009.05.00610.1016/j.addr.2009.05.006 ↗
18. 10.1016/0169-409X(95)00026-410.1016/0169-409X(95)00026-4 ↗
19. 10.1016/j.urolonc.2007.03.01510.1016/j.urolonc.2007.03.015 ↗
20. 10.1023/B:PHAM.0000045229.87844.2110.1023/B:PHAM.0000045229.87844.21 ↗
21. 10.1158/1078-0432.CCR-12-276410.1158/1078-0432.CCR-12-2764 ↗
22. 10.4155/tde.10.1310.4155/tde.10.13 ↗
23. 10.1021/bm049347a10.1021/bm049347a ↗
24. 10.3322/canjclin.55.1.1010.3322/canjclin.55.1.10 ↗
25. 10.1080/71381758310.1080/713817583 ↗
26. 10.1016/S0169-409X(00)00124-110.1016/S0169-409X(00)00124-1 ↗
27. 10.1002/1521-3927(20020101)23:1<26::AID-MARC26>3.0.CO;2-I10.1002/1521-3927(20020101)23:1<26::AID-MARC26>3.0.CO;2-I ↗
28. 10.1016/S0168-3659(01)00275-910.1016/S0168-3659(01)00275-9 ↗
29. 10.1038/sj.bjc.660130310.1038/sj.bjc.6601303 ↗
30. 10.1002/mabi.20080022910.1002/mabi.200800229 ↗
31. 10.1080/026520403100009303210.1080/0265204031000093032 ↗
32. 10.1007/s12272-011-0220-210.1007/s12272-011-0220-2 ↗
33. 10.1016/S0169-409X(02)00016-910.1016/S0169-409X(02)00016-9 ↗
34. 10.1002/jps.1053310.1002/jps.10533 ↗
35. 10.1002/jps.2099210.1002/jps.20992 ↗
36. 10.1007/s00280-006-0256-z10.1007/s00280-006-0256-z ↗
37. Malzert-Freon A · . · 2006 · 320 · 157
38. 10.3923/tmr.2007.128.13410.3923/tmr.2007.128.134 ↗
39. 10.1038/sj.bjc.660149410.1038/sj.bjc.6601494 ↗
40. 10.1054/bjoc.2000.117410.1054/bjoc.2000.1174 ↗
41. 10.1016/S0939-6411(00)00087-410.1016/S0939-6411(00)00087-4 ↗
42. Muller HR · Eur J Pharm Biopharm · 1995 · 41 · 62
43. Ozols R · Tumori · 1999 · 85 · S5
44. 10.1016/S1535-6108(04)00002-910.1016/S1535-6108(04)00002-9 ↗
45. Piel G · STP Pharma Sci · 1999 · 9 · 257
46. Purgholami MH · Anticancer Res · 2008 · 28 · 2775
47. Siekmann B · Pharmacol Lett · 1994 · 3 · 194
48. 10.3109/1071754100366776410.3109/10717541003667764 ↗
49. 10.1016/j.ygyno.2004.09.04610.1016/j.ygyno.2004.09.046 ↗
50. 10.3109/1061186960899683110.3109/10611869608996831 ↗
51. 10.1007/s10847-008-9456-y10.1007/s10847-008-9456-y ↗
52. Vyas A · Oriental J Chemistry · 2011 · 27 · 359
53. 10.1007/s10847-009-9605-y10.1007/s10847-009-9605-y ↗
54. 10.1186/1757-2215-3-1910.1186/1757-2215-3-19 ↗
55. 10.1038/sj.clpt.610040010.1038/sj.clpt.6100400 ↗
56. 10.1166/jnn.2010.281910.1166/jnn.2010.2819 ↗
57. 10.1016/j.canlet.2004.03.04810.1016/j.canlet.2004.03.048 ↗